MétaCan
Menu
Back to cohort
Record W2968618875 · doi:10.1093/jncics/pkz050

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

2019· article· en· W2968618875 on OpenAlexaffabout
Ryan J.O. Dowling, Kevin Kalinsky, Daniel F. Hayes, François‐Clément Bidard, David W. Cescon, Sarat Chandarlapaty, Joseph O. Deasy, Mitch Dowsett, Robert J. Gray, N. Lynn Henry, Funda Meric‐Bernstam, Jane Perlmutter, George W. Sledge, Scott V. Bratman, Lisa A. Carey, Martin C. Chang, Angela DeMichele, Marguerite Ennis, Katarzyna J. Jerzak, Larissa A. Korde, Ana Elisa Lohmann, Eleftherios P. Mamounas, Wendy R. Parulekar, Meredith M. Regan, Daniel Schramek, Vuk Stambolic, Mangesh A. Thorat, Timothy J. Whelan, Antonio C. Wolff, James R. Woodgett, Joseph A. Sparano, Pamela J. Goodwin

Bibliographic record

VenueJNCI Cancer Spectrum · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsMcMaster UniversityQueen's UniversityLunenfeld-Tanenbaum Research InstituteHealth Sciences CentreJuravinski Cancer CentreSinai Health SystemSunnybrook Health Science CentrePrincess Margaret Cancer CentreStatistics CanadaUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsMedicineContext (archaeology)Breast cancerDiseaseCancerCancer recurrenceEstrogen receptorIntensive care medicineOncologyGynecologyInternal medicine

Abstract

fetched live from OpenAlex

Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original diagnosis, and represent a major obstacle to the effective treatment of this disease. Indeed, methods to identify patients at risk of late recurrence and therapeutic strategies designed to avert or treat these recurrences are lacking. Therefore, an international workshop was convened in Toronto, Canada, in February 2018 to review the current understanding of late recurrence and to identify critical issues that require future study. In this article, the major issues surrounding late recurrence are defined and current approaches that may be applicable to this challenge are discussed. Specifically, diagnostic tests with potential utility in late-recurrence prediction are described as well as a variety of patient-related factors that may influence recurrence risk. Clinical and therapeutic approaches are also reviewed, with a focus on patient surveillance and the implementation of extended endocrine therapy in the context of late-recurrence prevention. Understanding and treating late recurrence in estrogen receptor-positive breast cancer is a major unmet clinical need. A concerted effort of basic and clinical research is required to confront late recurrence and improve disease management and patient survival.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.050
Threshold uncertainty score0.099

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0020.002
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0070.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.351
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations26
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueJNCI Cancer SpectrumSame topicBreast Cancer Treatment StudiesFrench-language works237,207